Immunicum AB announced the establishment of an updated executive management team following the initial integration period of the business combination with DCprime that was completed in December 2020. In the new composition, the executive management team Sven Rohmann, M.D., Ph.D., will remain associated with Immunicum as a business development advisor. Sharon Longhurst, Ph.D., will continue to serve as Head of CMC and Sijme Zeilemaker, MSc, will take the new role of Head of Investor Relations and Corporate Communication. Margareth Jorvid, MSc Pharm, will resign as Head of Regulatory and Quality Assurance.